{
    "data": [
        {
            "id": "69036880ecb8a70001457f05",
            "title": "Analysts Warn Fed&#39;s Balance Sheet Shift Could Have &#39;Larger Impact&#39; Than Interest Rates In The Near Future",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">The Federal Reserve's <a href=\"https://www.benzinga.com/markets/equities/25/10/48513895/stock-market-today-news-update-interest-rates\" target=\"_blank\">latest decision</a> to pause its long-running balance sheet reduction may have a greater medium-term impact on financial markets than its current interest rate path, analysts have warned.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Stocks Seen Driven By AI Optimism In Near Term</h2><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The shift in liquidity could dampen sentiment, though a gradual recovery may follow as asset purchases resume in line with the banking system's growth, <a href=\"https://www.investing.com/news/economy-news/fed-liquidity-may-be-a-key-market-driver-in-intermediate-term--wolfe-research-4319177?ref\" target=\"_blank\">reported </a>Investing.com, citing <strong>Wolfe Research</strong> analysts, <strong>Chris Senyek </strong>and<strong> Adam Calingasan</strong>.</p><!--/$--><!--$--><p class=\"block core-block\">“The Fed’s decision to end the reduction of Treasury Securities points to a changing liquidity picture in the months ahead, with reserves set to potentially shrink,” the analysts wrote in a Thursday note. </p><!--/$--><!--$--><p class=\"block core-block\">While reserve fluctuations are expected to have a “larger impact” on markets over the “intermediate term”, analysts noted that “the key question” is whether stocks will move based on liquidity concerns or sustained optimism around corporate <a href=\"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/10/48472094/meta-ad-business-100-billion-ai-bet-are-key-growth-drivers\" target=\"_blank\">artificial intelligence spending</a>. “We believe the latter in the near term,” they added.</p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><!--/$--><!--$--><h2 class=\"wp-block-heading\">Powell Rules Out December Rate Cut</h2><!--/$--><!--$--><p class=\"block core-block\">The Fed’s decision to halt its balance sheet reduction comes after it <a href=\"https://www.benzinga.com/markets/macro-economic-events/25/10/48506713/federal-reserve-decision-october-30-25-basis-point-fed-funds-rate-balance-sheet-qt-quantitative-tightening\" target=\"_blank\">cut its benchmark</a> interest rate by 25 basis points to a target range of 3.75%-4.00% and announced a halt to the runoff of its security holdings starting in December. This move was widely anticipated and marked the end of the quantitative tightening program that began in mid-2022.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">However, the Fed Chair <a href=\"https://www.benzinga.com/markets/economic-data/25/10/48510387/jerome-powell-press-conference-fed-meeting-october-30-interest-rate-outlook-market-reactions\" target=\"_blank\">Jerome Powell cautioned</a> that another rate cut in December is “far from a foregone conclusion,” leading to a sharp repricing in December expectations.</p><!--/$--><!--$--><p class=\"block core-block\">Meanwhile, Sen. <strong>Elizabeth Warren</strong> (D-Mass.)<a href=\"https://www.benzinga.com/markets/macro-economic-events/25/10/48516847/elizabeth-warren-says-fed-is-flying-blind-on-interest-rate-decision-families-deserve-the-facts-about-the-economy-not-more-lies-from-trump\" target=\"_blank\"> has criticized </a>the Trump administration for withholding key economic data, stating that the Federal Reserve was “flying blind” ahead of its interest rate decisions, adding another layer of uncertainty to the current economic landscape.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48526804\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><p class=\"block core-block\"><strong>READ NEXT:</strong></p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/markets/economic-data/25/10/48524312/trump-loyalist-stephen-mirans-utterly-incoherent-case-for-rate-cuts-convinces-no-one-says-economist-after-his-dissent\" target=\"_blank\">Trump Loyalist Stephen Miran’s ‘Utterly Incoherent Case For Rate Cuts’ Convinces ‘No-One,’ Says Economist After His Dissent<br/></a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Image via Shutterstock</em></p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\"><br/><br/></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/On-The-Smartphone-Screen--Federal-Reserv.jpeg",
            "link": "https://www.benzinga.com/markets/economic-data/25/10/48526804/analysts-warn-feds-balance-sheet-shift-could-have-larger-impact-than-interest-rates-in-the-near-future",
            "pub_date": "2025-10-30 21:30:43",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "690368ddecb8a70001457f22",
            "title": "This Draganfly Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href=\"https://www.benzinga.com/analyst-stock-ratings\" target=\"_blank\">analyst ratings page</a>.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>Needham analyst Austin Bohlig initiated coverage on <strong>Draganfly Inc</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/DPRO\" target=\"_blank\">DPRO</a>) with a Buy rating and announced a price target of $20. Draganfly shares closed at $8.55 on Wednesday. <a href=\"https://www.benzinga.com/quote/dpro/analyst-ratings\" target=\"_blank\">See how other analysts view this stock</a>.</li>\n<li>Chardan Capital analyst James McIlree initiated coverage on <strong>Kodiak AI Inc</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/KDK\" target=\"_blank\">KDK</a>) with a Buy rating and announced a price target of $22. Kodiak AI shares closed at $9.17 on Wednesday. <a href=\"https://www.benzinga.com/quote/kdk/analyst-ratings\" target=\"_blank\">See how other analysts view this stock</a>.</li>\n<li>Edward Jones analyst Soumit Roy initiated coverage on <strong>Evaxion A/S</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/EVAX\" target=\"_blank\">EVAX</a>) with a Buy rating and announced a price target of $10. Evaxion shares closed at $5.75 on Wednesday. <a href=\"https://www.benzinga.com/quote/AFRM/analyst-ratings\" target=\"_blank\">See how other analysts view this stock</a>.</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\">Considering buying DPRO stock? Here’s what analysts think: </p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\"><strong>Read This Next: </strong></p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48519346/top-wall-street-forecasters-revamp-amazon-expectations-ahead-of-q3-earnings\" target=\"_blank\">Top Wall Street Forecasters Revamp Amazon Expectations Ahead Of Q3 Earnings</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\">Photo via Shutterstock</p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-middle-48526857\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Analysts.jpeg",
            "link": "https://www.benzinga.com/analyst-stock-ratings/initiation/25/10/48526857/this-draganfly-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-thursday",
            "pub_date": "2025-10-30 21:32:17",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903645aecb8a70001457d8e",
            "title": "Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Takeda Pharmaceutical Company Limited</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/TAK\" target=\"_blank\">TAK</a>) posted a <a href=\"https://www.benzinga.com/pressreleases/25/10/b48518776/takeda-reports-first-half-fy2025-results-with-business-fundamentals-tracking-as-planned-updates-fu\" rel=\"noreferrer noopener\" target=\"_blank\">second-quarter 2025 </a>adjusted net profit of 201.6 billion Japanese yen (approximately $1.31 billion).</p><!--/$--><!--$--><p class=\"block core-block\">The company reported earnings per American Depositary Share (EPADS) of 43 cents, missing analyst <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">expectations of 44 cents</a>. However, in yen, earnings per share declined 4.5% to 128 yen.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Total sales for the quarter amounted to $7.52 billion (1.18 trillion yen), missing the consensus estimates of $8.08 billion.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Also Read: <a href=\"https://www.benzinga.com/news/health-care/25/10/48209315/takeda-taps-nabla-bios-generative-ai-platform-for-antibody-design-in-1-billion-pact\" rel=\"noreferrer noopener\" target=\"_blank\">Takeda Taps Nabla Bio’s Generative AI Platform For Antibody Design In $1 Billion Pact</a></strong></p><!--/$--><!--$--><p class=\"block core-block\">\"Takeda's fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of transition to a new phase focusing on new product launches. Our updated full-year outlook reflects impairment charges associated with strategic pipeline decisions taken in Q2 and transactional FX…,” Takeda CEO <strong>Christophe Weber</strong> said.</p><!--/$--><!--$--><div class=\"sc-SfCGz ciVbir\"></div><!--/$--><!--$--><p class=\"block core-block\">First half 2025 sales fell 6.9% (-3.9% at constant currency) to 2.22 trillion yen, while core operating profit slumped 11.2% to 639.2 billion yen.</p><!--/$--><!--$--><p class=\"block core-block\">The decline was primarily due to a decrease in Neuroscience revenue, mainly from the continued impact of generic erosion of Vyvanse for attention deficit hyperactivity disorder (ADHD).</p><!--/$--><!--$--><p class=\"block core-block\">Second quarter Neuroscience <a href=\"https://assets-dam.takeda.com/image/upload/v1761806490/Global/Investor/Financial-Results/FY2025/Q2/qr2025_q2_qfr_en.pdf\" rel=\"noreferrer noopener\" target=\"_blank\">sales</a> fell 33% to 97.5 billion yen, vaccine sales were down 21.1% to 20.2 billion yen, and cancer drug sales were up 4.3% to 149.1 billion yen.</p><!--/$--><!--$--><p class=\"block core-block\">Gastrointestinal sales rose 2% to 353.5 billion yen, while rare diseases revenue fell 2.7% to 184.1 billion yen.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Outlook</strong></p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">Takeda has <a href=\"https://assets-dam.takeda.com/image/upload/v1761806800/Global/Investor/Financial-Results/FY2025/Q2/FY2025_Q2_Press_Release_1030.pdf\" rel=\"noreferrer noopener\" target=\"_blank\">updated</a> its full-year 2025 outlook to reflect foreign exchange impacts and impairment charges related to the cell therapy platform.</p><!--/$--><!--$--><p class=\"block core-block\">Takeda revised its core revenue guidance from 4.53 trillion yen to 4.50 trillion yen.</p><!--/$--><!--$--><p class=\"block core-block\">The Japanese drug maker expects core operating profit of 1.13 trillion yen<span style=\"box-sizing:border-box;margin:0px;padding:0px\">, <a href=\"https://www.benzinga.com/markets/earnings/25/07/46737233/takeda-pharma-maintains-outlook-even-as-vyvanse-generics-hit-sales\" rel=\"noopener\" target=\"_blank\">down from prior guidance</a> of 1.14 trillion yen, and core earnings of 479 yen, </span>down from previous guidance of 485 yen.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action:</strong> TAK stock is trading 2.25% lower at $13.46 in the premarket at the last check on Thursday.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48526401\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/news/health-care/25/10/48486716/trump-administration-move-could-put-medical-debt-back-on-us-credit-reports-experts-warn-of-chilling-effect\" rel=\"noreferrer noopener\" target=\"_blank\">Trump Administration Move Could Put Medical Debt Back On US Credit Reports, Experts Warn Of ‘Chilling Effect’</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Takeda-Pharmaceutical-Company.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48526401/takeda-lowers-2025-outlook-after-weak-q2-and-pipeline-impairment-charges",
            "pub_date": "2025-10-30 21:13:01",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "690366c7ecb8a70001457eb0",
            "title": "XPO Surpasses Q3 Earnings Expectations, CEO Says NA Segment &#39;Outperforms Seasonality&#39;",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>XPO, Inc.</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/XPO\" target=\"_blank\">XPO</a>) shares are trading higher premarket on Thursday after the company reported <a href=\"https://www.benzinga.com/pressreleases/25/10/g48521973/xpo-reports-third-quarter-2025-results\" rel=\"noreferrer noopener\" target=\"_blank\">third-quarter 2025 financial results</a>.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Details</h2><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Revenue reached $2.11 billion for the quarter, surpassing estimates of $2.07 billion.</p><!--/$--><!--$--><p class=\"block core-block\">On an adjusted basis, net income was $128 million for the quarter, compared to $122 million in the third quarter of 2024. Adjusted EPS of $1.07 exceeded <a href=\"https://www.benzinga.com/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">the analyst consensus of $1.02</a>.</p><!--/$--><!--$--><p class=\"block core-block\">XPO's operating income declined to $164 million from $176 million in the same period last year.</p><!--/$--><!--$--><p class=\"block core-block\"><strong><em>Also Read: </em></strong><em><a href=\"https://www.benzinga.com/trading-ideas/movers/25/10/48056036/trucking-company-stocks-are-climbing-monday-whats-driving-the-rally\" rel=\"noreferrer noopener\" target=\"_blank\">Trucking Company Stocks Are Climbing: What’s Driving The Rally?</a></em></p><!--/$--><!--$--><p class=\"block core-block\">Adjusted EBITDA for the third quarter was $342 million, an increase from $333 million in the prior year.</p><!--/$--><!--$--><p class=\"block core-block\">XPO generated $371 million in operating cash flow and ended the quarter with $335 million in cash and cash equivalents.</p><!--/$--><!--$--><p class=\"block core-block\">The company repurchased $50 million of shares in the third quarter. </p><!--/$--><!--$--><div class=\"sc-SfCGz ciVbir\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Segment Performance</h2><!--/$--><!--$--><p class=\"block core-block\">XPO's North American Less-Than-Truckload (LTL) segment revenue stood at $1.26 billion, a 0.3% increase year over year (Y/Y), attributed to a 3.5% Y/Y decline in shipments per day and a 6.1% Y/Y drop in tonnage per day.</p><!--/$--><!--$--><p class=\"block core-block\">LTL segment achieved an adjusted operating ratio of 82.7%, a 150-basis-point improvement year-over-year, which CEO <strong>Mario Harik</strong> referred to as \"significantly outperforming seasonality.\"</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">Yield, excluding fuel, increased by 5.9% Y/Y, and revenue per shipment (excluding fuel surcharges) grew by 3.4% Y/Y in the quarter.</p><!--/$--><!--$--><p class=\"block core-block\">Adjusted EBITDA for the North American LTL segment increased 8.5% Y/Y to $308 million in the quarter.</p><!--/$--><!--$--><p class=\"block core-block\">Meanwhile, the European Transportation segment reported revenue of $857 million, up 6.7% Y/Y. However, adjusted EBITDA for this segment declined to $38 million from $44 million in the prior year.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action:</strong> XPO shares are up 1.60% to $126.75 in premarket trading at the last check on Thursday.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48526681\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/node/48496887\" rel=\"noreferrer noopener\" target=\"_blank\">ODFL Shares Jump As Q3 Earnings Top Forecasts Despite Freight Slowdown</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/XPO--Inc.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48526681/xpo-surpasses-q3-earnings-expectations-ceo-says-na-segment-outperforms-seasonality",
            "pub_date": "2025-10-30 21:23:23",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69035d2decb8a70001457954",
            "title": "Kimberly-Clark Proves Resilient With Firm Sales In Shifting Market",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Kimberly-Clark Corporation</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/KMB\" target=\"_blank\">KMB</a>) shares were trading higher in the premarket session on Thursday after the company <a href=\"https://www.benzinga.com/pressreleases/25/10/n48521515/kimberly-clark-announces-third-quarter-2025-results-updates-2025-outlook\" rel=\"noreferrer noopener\" target=\"_blank\">reported third-quarter fiscal 2025 results</a>.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Key Figures</h2><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The company reported adjusted earnings per share of $1.82, beating the analyst consensus estimate of $1.76.</p><!--/$--><!--$--><p class=\"block core-block\">Quarterly sales of $4.15 billion, flat year over year (Y/Y), surpassed the street view of $4.12 billion.</p><!--/$--><!--$--><p class=\"block core-block\">Sales reflect a 2.2% headwind from the U.S. private label diaper exit. Organic sales rose 2.5% Y/Y, led by 2.4% volume growth in the quarter.</p><!--/$--><!--$--><p class=\"block core-block\"><strong><em>Also Read:</em> <em><a href=\"https://www.benzinga.com/news/legal/25/08/47420402/kimberly-clark-to-pay-around-40-million-over-surgical-gown-designs\" rel=\"noreferrer noopener\" target=\"_blank\">Kimberly-Clark To Pay Around $40 Million Over Surgical Gown Designs</a></em></strong></p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Segment Performance</h2><!--/$--><!--$--><p class=\"block core-block\">North American net sales decreased 0.8% Y/Y to $2.7 billion in the quarter, due to the exit of the company’s private label diaper business in the U.S.</p><!--/$--><!--$--><p class=\"block core-block\">Meanwhile, International Personal Care net sales increased 1.9% Y/Y to $1.4 billion, with organic sales growth of 2.1% Y/Y.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Bottom Line</h2><!--/$--><!--$--><p class=\"block core-block\">Adjusted gross margin was 36.8%, down 170 basis points from the prior year, owing to unfavorable pricing net of cost inflation and higher tariff-related costs.</p><!--/$--><!--$--><p class=\"block core-block\">Adjusted operating profit was $683 million, unchanged from last year, as efficiency gains and lower incentive accruals offset gross margin headwinds.</p><!--/$--><!--$--><p class=\"block core-block\">The net income of equity companies was $46 million, in line with million in the prior year.</p><!--/$--><!--$--><p class=\"block core-block\">Total debt was $7.3 billion as of September 30, down from $7.4 billion as of December 31, 2024.</p><!--/$--><!--$--><p class=\"block core-block\">Kimberly-Clark exited the quarter with cash and equivalents worth $617 million.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">“The operating environment remains dynamic, but we continue to execute our strategy with discipline and excellence as we play to win,” said Kimberly-Clark Chairman and CEO <strong>Mike Hsu</strong>.</p><!--/$--><!--$--><p class=\"block core-block\">The company said its performance was driven by resilient consumer demand, pioneering product innovations, and sustained industry-leading productivity.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Outlook</h2><!--/$--><!--$--><p class=\"block core-block\">For 2025, the company <a href=\"https://www.benzinga.com/calendars/guidance\" rel=\"noreferrer noopener\" target=\"_blank\">expects organic sales</a> to grow roughly in line with the weighted average growth of its categories and markets, currently around 2%.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Kimberly-Clark expects to face a ~100-basis-point headwind from currency translation and a ~290-basis-point impact from the PPE divestiture and U.S. private label diaper exit.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects 2025 adjusted operating profit to grow at a low single-digit rate on a constant-currency basis, with a ~380-basis-point headwind from the PPE divestiture and U.S. private label diaper exit, and an additional ~70-basis-point impact from currency translation.</p><!--/$--><!--$--><p class=\"block core-block\">Kimberly-Clark projects adjusted EPS to grow at a low-to-mid single-digit rate on a constant-currency basis, including a ~320-basis-point headwind from the divestiture and diaper exit.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action: </strong>KMB shares were trading higher by 3.43% to $120.72 premarket at last check Thursday.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48525315\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><em><a href=\"https://www.benzinga.com/node/48446177\" rel=\"noreferrer noopener\" target=\"_blank\">P&amp;G Holds Its Premium As Analysts Cite Durable Growth Beyond Near-Term Tariff Hits</a></em></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by JHVEPhoto Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Irving--Texas--Usa---March-20--2022-Kimb.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48525315/kimberly-clark-proves-resilient-with-firm-sales-in-shifting-market",
            "pub_date": "2025-10-30 20:42:24",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}